Erenumab-aooe 140 mg/ML [Aimovig]
RxNorm 2120194
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2120194 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: erenumab-aooe 140 mg/ML [Aimovig].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDCPrescribable
Semantic Branded Drug Component (SBDC):
Erenumab-aooe 140 mg/ML [Aimovig]
(Atom ID: 10828635)
Patient Education
Erenumab-aooe Injection
Erenumab-aooe injection is used to help prevent migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). Erenumab-aooe injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes migraine headaches.
[Learn More]
* Please review the disclaimer below.